In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Prime Medicine Inc’s stock clocked out at $1.18, down -6.35% from its previous closing price of $1.26. In other words, the price has decreased by -$6.35 from its previous closing price. On the day, 1.34 million shares were traded.
Ratios:
To gain a deeper understanding of PRME’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.07.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 20 ’25 when Brudnick Richard bought 20,000 shares for $1.19 per share. The transaction valued at 23,790 led to the insider holds 20,000 shares of the business.
LEE ANN L. bought 100,000 shares of PRME for $113,000 on May 21 ’25. The Chief Technical Officer now owns 100,000 shares after completing the transaction at $1.13 per share. On May 21 ’25, another insider, Reine Allan, who serves as the Chief Executive Officer of the company, bought 125,000 shares for $1.18 each. As a result, the insider paid 147,150 and bolstered with 125,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 40.24 while its Price-to-Book (P/B) ratio in mrq is 1.45.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $8.14, while it has fallen to a 52-week low of $1.11. The 50-Day Moving Average of the stock is -21.64%, while the 200-Day Moving Average is calculated to be -58.84%.
Shares Statistics:
A total of 131.16M shares are outstanding, with a floating share count of 51.73M. Insiders hold about 60.60% of the company’s shares, while institutions hold 28.65% stake in the company.
Earnings Estimates
Currently, 9.0 analysts are dedicated to thoroughly evaluating and rating the performance of Prime Medicine Inc (PRME) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.25 and low estimates of -$0.31.
Analysts are recommending an EPS of between -$1.04 and -$1.37 for the fiscal current year, implying an average EPS of -$1.22. EPS for the following year is -$0.89, with 10.0 analysts recommending between -$0.67 and -$1.4.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $50M, while the lowest revenue estimate was $1.45M, resulting in an average revenue estimate of $14.64M. In the same quarter a year ago, actual revenue was $2.98M
